-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
-
Summary
-
CNS Pharmaceuticals, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q1 2018 to Q3 2024.
- CNS Pharmaceuticals, Inc. Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2024 was -$5.61M, a 23.9% decline year-over-year.
- CNS Pharmaceuticals, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2024 was -$17.1M, a 8.36% increase year-over-year.
- CNS Pharmaceuticals, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$18.9M, a 23.4% decline from 2022.
- CNS Pharmaceuticals, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$15.3M, a 5.37% decline from 2021.
- CNS Pharmaceuticals, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$14.5M, a 53.3% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)